What Is Stem Cell Potency? A Plain-Language Guide to Totipotent, Pluripotent, and Multipotent Cells

Every stem cell has a "job description" written into it — a range of cell types it is capable of becoming — and biologists call that range its potency. Understanding potency is one of the most useful mental models for making sense of stem cell science, because it explains why a fertilized egg can build an entire human being while a stem cell in your bone marrow can only build blood. This guide walks through the potency hierarchy from totipotent down to unipotent, with real-world examples at each level, and explains why this concept isn't just academic trivia — it directly determines what a given stem cell can be used for therapeutically, and how much manufacturing and safety complexity comes with it.

What "Potency" Actually Means

In developmental biology, potency describes how many different cell types a single stem cell is able to differentiate into. Think of it as a spectrum running from maximum flexibility to near-total specialization. At one end sit cells that can, in principle, generate any tissue in the body (or even an entire organism); at the other end sit cells so committed to a single job that they can only ever produce one type of descendant. The five traditional tiers, from most to least flexible, are totipotent, pluripotent, multipotent, oligopotent, and unipotent. As cells divide and specialize during development, they generally move down this ladder — gaining identity and function while losing options.

Totipotent Cells: The Ultimate Starting Point

Totipotent cells sit at the top of the hierarchy. The textbook example is the zygote — the single cell formed the moment a sperm fertilizes an egg — along with the very first cells produced when it divides. A totipotent cell can generate every cell type in the developing embryo and body, and it can also generate the extra-embryonic tissues, like the placenta and umbilical cord, that support the embryo but never become part of the body itself. That quality is what makes totipotency unique and, practically speaking, extremely short-lived: within the first few divisions after fertilization, cells begin losing this full range and become pluripotent instead.

Pluripotent Cells: Any Body Cell, But Not a Whole Organism

A few days after fertilization, the embryo forms a structure called the blastocyst, which contains a cluster of cells called the inner cell mass. These cells are pluripotent: they can still become virtually any cell type found in the adult body — neurons, heart muscle, liver, skin, bone, blood — but they can no longer form the extra-embryonic support tissues. Embryonic stem cells (hESCs), first derived from this inner cell mass in 1998, are the classic pluripotent cell line used in research. The other major pluripotent cell type is the induced pluripotent stem cell (iPSC), created in 2006 when researchers discovered that adult cells could be reprogrammed back into an embryonic stem cell–like state by activating a specific set of genes. iPSCs matter enormously because they let scientists generate patient-specific pluripotent cells without using embryos at all.

Multipotent Cells — and Their More Restricted Cousins

Below pluripotent sits multipotent, the tier most adult, tissue-resident stem cells occupy. A multipotent stem cell can produce multiple related cell types within one particular lineage or organ system, but not cell types from unrelated tissues. Hematopoietic stem cells, found in bone marrow and cord blood, are multipotent: they can become red blood cells, the various types of white blood cells, and platelets — the whole blood system — but not a neuron or a liver cell. Mesenchymal stem cells, found in bone marrow, fat, and other connective tissues, are another well-known multipotent type, generally able to give rise to bone, cartilage, and fat-lineage cells. Beyond multipotent, the hierarchy narrows further into oligopotent cells, which can generate only a small number of closely related cell types (a myeloid progenitor cell producing several types of white blood cells, for instance), and finally unipotent cells, which normally produce just one differentiated cell type — such as the epidermal stem cells that continually replenish skin. Unipotent cells are still considered "stem cells" rather than ordinary body cells because they retain the ability to self-renew indefinitely, even though their differentiation output is limited to a single lane.

Why Potency Matters for Therapy Design

Potency isn't just a classification exercise — it's the variable that determines what a stem cell can realistically be used to treat. A pluripotent cell is, in theory, a universal raw material: researchers can direct it down almost any developmental pathway to produce replacement cells for a huge range of conditions. A multipotent cell, by contrast, is naturally suited to regenerating the specific tissue system it already belongs to — which is precisely why bone-marrow– and cord-blood–derived hematopoietic stem cell transplantation has been used for decades to treat blood cancers and immune disorders. Hematopoietic stem cell transplantation remains the only stem cell–based therapy routinely approved for standard clinical use; treatments built on pluripotent (embryonic or induced) stem cells are still considered experimental and are being tested in clinical trials rather than offered as approved standard care.

The Safety and Manufacturing Tradeoffs of Higher Potency

Greater flexibility comes at a cost. Because pluripotent cells are capable of becoming almost anything, any cells that are not fully and correctly differentiated before transplantation carry a real risk of forming a teratoma — a tumor made up of a disorganized mix of tissue types — if they continue dividing unchecked inside the body. A 2012 analysis in Nature Biotechnology by Cunningham and colleagues examined naturally occurring human teratomas specifically to help researchers better predict and manage this risk in pluripotent-cell-derived therapies, underscoring that eliminating residual undifferentiated cells is a major manufacturing and quality-control challenge. Multipotent adult stem cells, precisely because their potential is narrower, are generally considered to carry a lower risk of this kind of uncontrolled growth and require less complex differentiation engineering — one major reason they reached approved clinical use first.

Bottom Line

Potency is the property that ties together nearly everything else you'll read about stem cells: it's why a fertilized egg can become an entire person, why embryonic stem cells and iPSCs are prized as an almost universal research and therapeutic resource, and why the bone-marrow transplants used to treat blood cancers today rely on multipotent, not pluripotent, cells. As a general rule, more potency means more therapeutic possibility — and more safety and manufacturing complexity to manage before that possibility can be safely delivered to a patient.